Victoza provides greater glycaemic control than SGLT-2 inhibitors
2 December 2015 | By Victoria White
Novo Nordisk has released new data that shows Victoza (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose cotransporter 2 inhibitors...